These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 30273189)

  • 1. Urinary Retention Associated With Cariprazine: A Case Report.
    Kapulsky L; Brody BD
    Clin Neuropharmacol; 2018; 41(6):230-231. PubMed ID: 30273189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aripiprazole associated urine retention in a male schizophrenia patient.
    Hsu WY; Chang TG; Chiu NY
    Gen Hosp Psychiatry; 2013; 35(6):680.e11-2. PubMed ID: 23932666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urinary hesitancy and retention caused by ziprasidone.
    Xomalis D; Bozikas VP; Garyfallos G; Nikolaidis N; Giouzepas J; Fokas K
    Int Clin Psychopharmacol; 2006 Jan; 21(1):71-2. PubMed ID: 16317320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aripiprazole in a patient susceptible to urinary side effects of antipsychotics.
    Sahoo S
    Isr J Psychiatry Relat Sci; 2007; 44(1):74-5. PubMed ID: 17668467
    [No Abstract]   [Full Text] [Related]  

  • 5. [Cariprazine for acute and maintenance treatment of schizophrenia].
    Spoelstra SK; Visser L; Knegtering H
    Tijdschr Psychiatr; 2019; 61(10):702-709. PubMed ID: 31907914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The safety and tolerability of cariprazine in long-term treatment of schizophrenia: a post hoc pooled analysis.
    Nasrallah HA; Earley W; Cutler AJ; Wang Y; Lu K; Laszlovszky I; Németh G; Durgam S
    BMC Psychiatry; 2017 Aug; 17(1):305. PubMed ID: 28836957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cariprazine:New dopamine biased agonist for neuropsychiatric disorders.
    De Deurwaerdère P
    Drugs Today (Barc); 2016 Feb; 52(2):97-110. PubMed ID: 27092339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urinary obstruction with citalopram and aripiprazole combination in an elderly patient.
    Padala PR; Sadiq HJ; Padala KP
    J Clin Psychopharmacol; 2006 Dec; 26(6):667-8. PubMed ID: 17110829
    [No Abstract]   [Full Text] [Related]  

  • 9. Cariprazine: A Review in Schizophrenia.
    Garnock-Jones KP
    CNS Drugs; 2017 Jun; 31(6):513-525. PubMed ID: 28560619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability.
    Citrome L
    Expert Opin Drug Metab Toxicol; 2013 Feb; 9(2):193-206. PubMed ID: 23320989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atypical antipsychotics for psychosis in adolescents.
    Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
    Cochrane Database Syst Rev; 2013 Oct; 2013(10):CD009582. PubMed ID: 24129841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cariprazine: First Global Approval.
    McCormack PL
    Drugs; 2015 Nov; 75(17):2035-43. PubMed ID: 26510944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urinary retention associated with ziprasidone: a case report.
    Mago R; Chism LM; Pinninti NR; Certa K
    J Clin Psychiatry; 2008 Mar; 69(3):499-500. PubMed ID: 18402503
    [No Abstract]   [Full Text] [Related]  

  • 14. [Urinary retention with risperidone].
    Siepmann M; Olbrich H
    Psychiatr Prax; 1997 Jul; 24(4):209. PubMed ID: 9340666
    [No Abstract]   [Full Text] [Related]  

  • 15. Acute urinary retention associated with selective serotonin reuptake inhibitors and ziprasidone.
    Chung AK; Chua SE
    J Clin Psychopharmacol; 2007 Oct; 27(5):517-9. PubMed ID: 17873690
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy and Safety of Cariprazine in Acute Exacerbation of Schizophrenia: Results From an International, Phase III Clinical Trial.
    Kane JM; Zukin S; Wang Y; Lu K; Ruth A; Nagy K; Laszlovszky I; Durgam S
    J Clin Psychopharmacol; 2015 Aug; 35(4):367-73. PubMed ID: 26075487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and tolerability of cariprazine in patients with acute exacerbation of schizophrenia: a pooled analysis of four phase II/III randomized, double-blind, placebo-controlled studies.
    Earley W; Durgam S; Lu K; Laszlovszky I; Debelle M; Kane JM
    Int Clin Psychopharmacol; 2017 Nov; 32(6):319-328. PubMed ID: 28692485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urinary retention associated with aripiprazole: Report of a new case and review of the literature.
    Boyer MG; Kheloufi F; Denis J; Micallef J; Milh M
    Therapie; 2018; 73(3):287-289. PubMed ID: 29146041
    [No Abstract]   [Full Text] [Related]  

  • 19. Tolerability and Safety Profile of Cariprazine in Treating Psychotic Disorders, Bipolar Disorder and Major Depressive Disorder: A Systematic Review with Meta-Analysis of Randomized Controlled Trials.
    Lao KS; He Y; Wong IC; Besag FM; Chan EW
    CNS Drugs; 2016 Nov; 30(11):1043-1054. PubMed ID: 27550371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical pharmacology study of cariprazine (MP-214) in patients with schizophrenia (12-week treatment).
    Nakamura T; Kubota T; Iwakaji A; Imada M; Kapás M; Morio Y
    Drug Des Devel Ther; 2016; 10():327-38. PubMed ID: 26834462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.